Cardiomyocyte and vascular smooth muscle-independent 11β-hydroxysteroid dehydrogenase 1 amplifies infarct expansion, hypertrophy, and the development of heart failure after myocardial infarction in male mice

Endocrinology

Volumn 157, Issue 1, 2016, Pages 346-357

  White, Christopher I ^a   Jansen, Maurits A ^a,b   McGregor, Kieran ^a   Mylonas, Katie J ^a   Richardson, Rachel V ^a   Thomson, Adrian ^b   Moran, Carmel M ^a,b   Seckl, Jonathan R ^a   Walker, Brian R ^a   Chapman, Karen E ^a   Gray, Gillian A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ATRIAL NATRIURETIC FACTOR; CRE RECOMBINASE; MYOSIN HEAVY CHAIN BETA; TRANSGELIN;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME DEFICIENCY; GENE DISRUPTION; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; LUNG EDEMA; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE CELL; WILD TYPE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; CROSS BREEDING; DEFICIENCY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEART STROKE VOLUME; HEART VENTRICLE; KNOCKOUT MOUSE; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY EDEMA; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; CARDIOMEGALY; CORONARY CIRCULATION; CROSSES, GENETIC; GENE EXPRESSION REGULATION; HEART FAILURE; HEART VENTRICLES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN SIZE; PULMONARY EDEMA; STROKE VOLUME;

EID: 84954530519     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1630     Document Type: Article

References (47)

1. Danchin N. Winning the battle against ST-segment-elevation myocardial infarction: continued progress, but still a long way to go. Eur Heart J. 2010;31:2580-2582.
2. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106:2351-2357.
3. Ibáñez B, Heusch G, Ovize M, Van De Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65:1454-1471.
4. Sluijter JP, Condorelli G, Davidson SM, et al. Novel therapeutic strategies for cardioprotection. Pharmacol Ther. 2014;144:60-70.
5. Cochain C, Channon KM, Silvestre JS. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal. 2013;18:1100-1113.
6. Emanueli C, Madeddu P. Therapeutic angiogenesis: translating experimental concepts to medically relevant goals. Vascul Pharmacol. 2006;45:334-339.
7. Loke P, Nair MG, Parkinson J, Guiliano D, Blaxter M, Allen JE. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol. 2002;3:7.
8. McSweeney SJ, Hadoke PW, Kozak AM, et al. Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11βHSD1-deficient mice post-MI. Cardiovasc Res. 2010;88:159-167.
9. Meloni M, Marchetti M, Garner K, et al. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther. 2013;21:1390-1402.
10. Small GR, Hadoke PW, Sharif I, et al. Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA. 2005;102:12165-12170.
11. Le Gal YM, Morrissey LL. Methylprednisolone interventions in myocardial infarction: a controversial subject. Can J Cardiol. 1990;6:405-410.
12. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest. 1973;52:599-607.
13. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-1312.
14. Chapman K, Holmes M, Seckl J. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93:1139-1206.
15. Anderson A, Walker BR. 11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs 2013;73:1385-1393.
16. McGregor K, Webster S, Mylonas K, White CI, Walker BR, Gray G. Immediate pharmacological inhibition of local glucocorticoid generation increases angiogenesis and improves cardiac function after myocardial infarction. Heart 2014;100(supp 3):A118.
17. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR. 11β-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension. 2003;42:580-587.
18. Dover AR, Hadoke PW, Macdonald LJ, Miller E, Newby DE, Walker BR. Intravascular glucocorticoid metabolism during inflammation and injury in mice. Endocrinology. 2007;148:166-172.
19. Gordon O, He Z, Gilon D, et al. A transgenic platform for testing drugs intended for reversal of cardiac remodeling identifies a novel 11βHSD1 inhibitor rescuing hypertrophy independently of re-vascularization. PLoS One 2014;9:e92869.
20. Kipari T, Hadoke PW, Iqbal J, et al. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J. 2013;27:1519-1531.
21. Lepore JJ, Cheng L, Min Lu M, Mericko PA, Morrisey EE, Parmacek MS. High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22α-Cre transgenic mice. Genesis. 2005;41:179-184.
22. Wang Y, Cao Y, Yamada S, et al. Cardiomyopathy and worsened ischemic heart failure in SM22-α Cre-mediated neuropilin-1 null mice: dysregulation of PGC1α and mitochondrial homeostasis. Arterioscler Thromb Vasc Biol. 2015;35:1401-1412.
23. Gray GA, Patrizio M, Sherry L, et al. Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction. Acta Histochem. 2010;112:413-423.
24. O'Brien PJ, Smith DE, Knechtel TJ, et al. Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim. 2006;40:153-171.
25. Gray GA, White CI, Thomson A, Kozak A, Moran C, Jansen MA. Imaging the healing murine myocardial infarct in vivo: ultrasound, magnetic resonance imaging and fluorescence molecular tomography. Exp Physiol. 2013;98:606-613.
26. De Sousa Peixoto RA, Turban S, Battle JH, Chapman KE, Seckl JR, Morton NM. Preadipocyte 11β-hydroxysteroid dehydrogenase type 1 is a keto-reductase and contributes to diet-induced visceral obesity in vivo. Endocrinology. 2008;149:1861-1868.
27. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-796.
28. Protti A, Dong X, Sirker A, Botnar R, Shah AM. MRI-based prediction of adverse cardiac remodeling after murine myocardial infarction. Am J Physiol Heart Circ Physiol. 2012;303:H309-H314.
29. Gaudron P, Kugler I, Hu K, Bauer W, Eilles C, Ertl G. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their inter-relation and prognostic impact. J Am Coll Cardiol. 2001;38:33-40.
30. Panagopoulou V, Deftereos S, Kossyvakis C, et al. NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem. 2013;13:82-94.
31. Krenz M, Sanbe A, Bouyer-Dalloz F, et al. Analysis of myosin heavy chain functionality in the heart. J Biol Chem. 2003;278:17466-17474.
32. Rahman TJ, Mayosi BM, Hall D, et al. Common variation at the 11-β hydroxysteroid dehydrogenase type 1 gene is associated with left ventricular mass. Circ Cardiovasc Genet. 2011;4:156-162.
33. Furtado MB, Costa MW, Pranoto EA, et al. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ Res. 2014;114:1422-1434.
34. Turner NA. Effects of interleukin-1 on cardiac fibroblast function: relevance to post-myocardial infarction remodelling. Vascul Pharmacol. 2014;60:1-7.
35. Fujiu K, Nagai R. Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol. 2014;70:64-73.
36. Hardy R, Juarez M, Naylor A, et al. Synovial DKK1 expression is regulated by local glucocorticoid metabolism in inflammatory arthritis. Arthritis Res Therap. 2012;14:R226.
37. Hardy RS, Filer A, Cooper MS, et al. Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissuespecific regulation of inflammation. Arthritis ResTherap. 2006;8:R108.
38. Chapman KE, Coutinho AE, Zhang Z, Kipari T, Savill JS, Seckl JR. Changing glucocorticoid action: 11β-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation. J Steroid Biochem Mol Biol. 2013;137:82-92.
39. Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunol Res. 2014;59:243-253.
40. Hadoke PW, Kipari T, Seckl JR, Chapman KE. Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation. Curr Atheroscler Rep. 2013;15:320.
41. Iqbal J, Macdonald LJ, Low L, et al. Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice. Endocrinology. 2012;153:5896-5905.
42. Mylonas KJ, Jenkins SJ, Castellan RF, et al. The adult murine heart has a sparse, phagocytically active macrophage population that expands through monocyte recruitment and adopts an 'M2' phenotype in response to Th2 immunologic challenge. Immunobiology. 2015;220:924-933.
43. Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782-2795.
44. Montalescot G, Pitt B, Lopez De Sa E, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind REMINDER Study. Eur Heart J. 2014;35:2295-2302.
45. Fraccarollo D, Galuppo P, Schraut S, et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension. 2008;51:905-914.
46. Fraccarollo D, Berger S, Galuppo P, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011;123:400-408.
47. Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASISHF). Circ Heart Fail. 2014;7:51-58.